JP2017524719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524719A5 JP2017524719A5 JP2017507823A JP2017507823A JP2017524719A5 JP 2017524719 A5 JP2017524719 A5 JP 2017524719A5 JP 2017507823 A JP2017507823 A JP 2017507823A JP 2017507823 A JP2017507823 A JP 2017507823A JP 2017524719 A5 JP2017524719 A5 JP 2017524719A5
- Authority
- JP
- Japan
- Prior art keywords
- esketamine
- patient
- depression
- pharmaceutical composition
- dosing regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims description 19
- 229960000450 esketamine Drugs 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 11
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 6
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 5
- 238000003205 genotyping method Methods 0.000 claims description 5
- 229960003299 ketamine Drugs 0.000 claims description 5
- 108700028369 Alleles Proteins 0.000 claims description 4
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000002858 neurotransmitter agent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 230000002068 genetic effect Effects 0.000 claims 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462036896P | 2014-08-13 | 2014-08-13 | |
| US62/036,896 | 2014-08-13 | ||
| PCT/US2015/044830 WO2016025581A1 (en) | 2014-08-13 | 2015-08-12 | Method for the treatment of depression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524719A JP2017524719A (ja) | 2017-08-31 |
| JP2017524719A5 true JP2017524719A5 (enExample) | 2018-09-20 |
| JP6545788B2 JP6545788B2 (ja) | 2019-07-17 |
Family
ID=55301311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017507823A Active JP6545788B2 (ja) | 2014-08-13 | 2015-08-12 | うつ病の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10098854B2 (enExample) |
| EP (1) | EP3179993B1 (enExample) |
| JP (1) | JP6545788B2 (enExample) |
| KR (1) | KR20170040800A (enExample) |
| CN (1) | CN106714789A (enExample) |
| AU (2) | AU2015301782B2 (enExample) |
| CA (1) | CA2957926A1 (enExample) |
| IL (2) | IL250490A0 (enExample) |
| MA (1) | MA40462A (enExample) |
| MX (1) | MX2017001908A (enExample) |
| WO (1) | WO2016025581A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| WO2015037248A1 (en) | 2013-09-13 | 2015-03-19 | National University Corporation Chiba University | Application of r-ketamine and salt thereof as pharmaceuticals |
| US9610259B2 (en) * | 2014-01-14 | 2017-04-04 | Children's Hospital Medical Center | Compositions and methods for treating an autism spectrum disorder |
| KR20170054470A (ko) | 2014-09-15 | 2017-05-17 | 얀센 파마슈티카 엔.브이. | VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법 |
| US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
| AU2016288188B2 (en) | 2015-06-27 | 2021-08-05 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US11491120B2 (en) | 2017-11-09 | 2022-11-08 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| IL275482B1 (en) | 2017-12-22 | 2025-03-01 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| EP3505157B1 (en) | 2017-12-29 | 2021-12-08 | Celon Pharma S.A. | Dry powder ketamine composition for pulmonary administration in treatment-resistant depression |
| EP3753557B1 (en) | 2018-02-15 | 2025-11-05 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| EP3813808A4 (en) | 2018-05-04 | 2022-01-26 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| EP3628313B1 (en) * | 2018-09-28 | 2025-02-12 | Novohale Therapeutics, LLC | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
| CN113632174B (zh) | 2019-01-23 | 2025-03-25 | 密歇根大学董事会 | 用于nmda、甘氨酸和ampa受体的调节剂的药物基因组学决策支持 |
| WO2020178653A1 (en) | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| US20210407643A1 (en) * | 2020-06-25 | 2021-12-30 | Greenway Dna Inc. | Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| JPS632932A (ja) | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
| ATE292956T1 (de) | 1998-07-24 | 2005-04-15 | Seo Hong Yoo | Klare wässrige lösungen enthaltend gallensäuren |
| US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
| EP1103256A1 (de) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
| MXPA05000294A (es) | 2002-07-30 | 2005-08-19 | Peter Migaly | Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas. |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
| JP2009530385A (ja) * | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| BRPI0711872A2 (pt) | 2006-05-22 | 2011-12-06 | Vanda Pharmaceuticals Inc | tratamento para distúrbios depressivos |
| DE102007009888A1 (de) * | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| WO2009131794A1 (en) | 2008-03-27 | 2009-10-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| US8846765B2 (en) | 2010-06-15 | 2014-09-30 | Gruenenthal Gmbh | Pharmaceutical combination |
| AU2012340015B2 (en) | 2011-11-14 | 2017-09-21 | Alfasigma S.P.A. | Assays for selecting a treatment regimen for a subject with depression and methods for treatment |
| US20130236573A1 (en) | 2012-03-12 | 2013-09-12 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| SG11201501292UA (en) | 2012-08-23 | 2015-05-28 | Stuart L Weg | Anxiolytic composition, formulation and method of use |
| EP2983787B1 (en) | 2013-04-12 | 2019-10-02 | Icahn School of Medicine at Mount Sinai | Method for treating post-traumatic stress disorder |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
-
2015
- 2015-08-12 CA CA2957926A patent/CA2957926A1/en not_active Abandoned
- 2015-08-12 MX MX2017001908A patent/MX2017001908A/es unknown
- 2015-08-12 EP EP15831762.8A patent/EP3179993B1/en active Active
- 2015-08-12 JP JP2017507823A patent/JP6545788B2/ja active Active
- 2015-08-12 MA MA040462A patent/MA40462A/fr unknown
- 2015-08-12 WO PCT/US2015/044830 patent/WO2016025581A1/en not_active Ceased
- 2015-08-12 AU AU2015301782A patent/AU2015301782B2/en not_active Ceased
- 2015-08-12 CN CN201580043454.XA patent/CN106714789A/zh active Pending
- 2015-08-12 US US14/824,513 patent/US10098854B2/en active Active
- 2015-08-12 KR KR1020177006277A patent/KR20170040800A/ko not_active Ceased
-
2017
- 2017-02-07 IL IL250490A patent/IL250490A0/en active IP Right Grant
-
2020
- 2020-12-03 AU AU2020281101A patent/AU2020281101A1/en not_active Abandoned
- 2020-12-21 IL IL279627A patent/IL279627A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524719A5 (enExample) | ||
| JP2017528483A5 (enExample) | ||
| Farlow et al. | Pharmacologic treatment of cognition in Alzheimer's dementia | |
| Bashir | Emerging therapies in Huntington’s disease | |
| Malhi et al. | Pharmacological management of unipolar depression | |
| JP2024133462A (ja) | 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム | |
| CA2923685A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| MX2017001908A (es) | Metodo para el tratamiento de la depresion. | |
| JP2017511377A5 (enExample) | ||
| JP2019514858A5 (enExample) | ||
| JP2015504871A5 (enExample) | ||
| JP2025137763A (ja) | 絶食条件下でのタシメルテオンの投与 | |
| JP2014502641A5 (enExample) | ||
| CN1832734A (zh) | 用于治疗抑郁症的取代的2－氨基1,2,3,4－四氢化萘 | |
| JP2015505564A5 (enExample) | ||
| JP2016506933A5 (enExample) | ||
| JP2017533220A5 (enExample) | ||
| Kim et al. | Association of 5-HT3B receptor gene polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting | |
| Pae et al. | Quetiapine XR: current status for the treatment of major depressive disorder | |
| JP2016510343A5 (enExample) | ||
| JP2015522603A5 (enExample) | ||
| JP2020516663A5 (enExample) | ||
| JP2014532758A5 (enExample) | ||
| Lima et al. | The effect of an inhibitor of gut serotonin (LP533401) during the induction of periodontal disease | |
| JP2019504860A5 (enExample) |